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Aaron Bossler, MD, PhD
Clinical Associate Professor and Director of the Molecular Pathology 
Laboratory and Molecular Infectious Disease Section
Aaron Bossler
Joined University of Iowa Department 
of Pathology:  2005 
Hometown:  
Van Horne, Iowa
When did you decide to go into a career 
in medicine? 
I enjoyed my biology and chemistry 
classes in high school and decided to 
pursue a biochemistry degree in college.  
Many of my classmates were pre-med 
and my mom who had been a nurse 
encouraged me to consider medicine. 
The summer after my sophomore year 
I took an offer to be a lab assistant in a 
cell biology research laboratory. After 
learning the basics like all undergrads of 
washing dishes, ordering supplies, etc., 
Chloe Bulinski, my advisor and head of 
the lab, started me on a research project 
examining microtubule function in mitosis 
and the inhibitory effects of the drug 
taxol, derivatives of which are now used 
in cancer chemotherapy. She introduced 
me to the career of a clinician scientist 
and the possibility of doing combined 
MD, PhD training. That experience 
propelled me into medicine and research 
and I was happy to accept a position to 













What made you choose academic 
pathology? 
I chose to study human papillomavirus 
(HPV) and its role in cervical cancer for 
my doctoral work, and my mentors, Drs. 
Tom Haugen and Lubomir Turek, are 
both pathologists. They encouraged me to 
consider pathology as a career. Dr. Cohen, 
then the new head of the Department of 
Pathology, recommended that I investigate 
a career in molecular pathology as he 
anticipated its importance to medicine. 
Fortunately I followed his advice and after 
completing residency in clinical pathology 
at Iowa, I did the molecular genetic 
pathology fellowship at the University of 
Pennsylvania in Philadelphia. 
What is your area of research?    
HPV and its role in squamous cell 
carcinoma which has expanded to include 
other tissue types including oral and rectal 
mucosa continue to interest me. I have 
worked with otolaryngologists and other 
researchers at the University of Iowa and 
the University of South Dakota to explore 
the increasing rate of HPV infection 
and mechanisms of transformation in 
oral carcinoma. I am also beginning a 
new project examining the rate of HPV 
infection in HIV positive individuals who 
“
”
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are at increased risk for anal squamous 
cell carcinoma in collaboration with 
researchers from Tufts University. 
What visions/goals do you have for the 
future of the Molecular Pathology Lab 
at UIHC?
Our goal is to provide innovative 
molecular diagnostic tests which 
advance the care of patients in this era 
of personalized healthcare. We are in 
the midst of dramatic change and the 
rapid pace of biomedical discovery 
has accelerated the need and utility 
for molecular diagnostic testing. The 
Department of Pathology has a long 
history of early adoption of vital new tests, 
and the Molecular Pathology Laboratory 
is continuing that tradition.  We have 
had the ability to analyze DNA and RNA 
for genetic conditions or 
for the presence of 
infectious agents for 










design to target 
these molecular 
changes the ability 
to determine therapy 
based on molecular analysis 
is becoming available. For example, 
lung cancer patients with EGFR mutations 
or colorectal cancer patients lacking 
KRAS mutations in the tumor cells may 
respond to specifically targeted therapy. 
In absence of FDA approved assays, 
the Molecular Pathology Laboratory 
developed and validated molecular testing 
for EGFR and KRAS mutations in tumor 
specimens. We have the capability to 
develop similar tests and are investing 
in new and evolving technologies. Our 
mission also includes educating our 
trainees, staff and clients on the effective 
utility of molecular diagnostic testing. 
Publications/Books:
 Bossler AD and Caliendo, AM. 
Molecular Methods in Diagnosis and 
Monitoring of Infectious Diseases. In: 
Tietz Textbook of Clinical Chemistry and 
Molecular Diagnostics, Fifth Edition. 
Burtis, Ashwood and Bruns, eds. New 
York, Elsevier, 2012.
  Arbefeville, SS and Bossler AD. 
Bronchiolitis in an Infant; Infection with 
Human Metapneumovirus. In: Diagnostic 
Molecular Pathology in Practice. Shrijver 
ed.Springer-Verlag, Berlin Heidelberg, 
2011.
  Arbefeville, SS and Bossler AD. 
Human Papillomavirus Infection and 
ASC-US Triage. In: Diagnostic Molecular 
Pathology in Practice. Shrijver ed. 
Springer-Verlag, Berlin Heidelberg, 2011.
 Bossler AD, Gunsolly CS, Pyne MT, 
Rendo A, Rachel J, Mills R, Miller M, 
Sipley J, Hillyard D, Jenkins S, Essmyer 
C, Young S, Lewinski M, Rennert H.  
Performance of the COBAS® Ampliprep/
COBAS TaqMan® Automated System for 
Hepatitis C Virus (HCV) Quantification in 
a Multi-center Comparison. J. Clin. Virol.: 
2011 Feb;50(2):100-3.
Honor/Awards/Appointments:
Member, Economic Affairs Committee, 
Association for Molecular Pathology (AMP)
AMP Representative to the Pathology 
Coding Caucus (PCC), American Medical 
Association 
Member, AMA Molecular Pathology CPT 
Coding Work Group (tasked with revising 
outdated CPT coding for molecular based 
laboratory testing)
Member, Economic Affairs Committee, 
College of American Pathology
Member, Editorial Board, Journal of 
Molecular Diagnostics
Professional Organizations:
Association for Molecular Pathology 
(AMP)
College of American Pathologists (CAP)
United States and Canadian Academy of 
Pathology (USCAP)
American Society for Microbiology (ASM) 
Pan American Society for Clinical 
Virology (PASCV)
American Society for Clinical Pathology 
(ASCP)
Iowa Association of Pathologists (IAP)
American Medical Association (AMA)
When not working, what are your 
personal interests and/or hobbies?  
Poverty and homelessness are social issues 
that concern me and I have worked with 
the Crisis Center of Johnson County to 
help those in need. I enjoy a great workout 
and like to bicycle, run, lift weights and 
ski. Having grown up on a farm instilled 
a desire to grow my own food, and I look 
forward to growing vegetables every 
spring. 
Any additional information you 
would like to add about the Molecular 
Pathology Service?
The Molecular Pathology Laboratory has 
talented and friendly staff and faculty 
who are available to answer questions 
and provide guidance for appropriate 
molecular testing. 
FACULTY	FOCUS
             continued
Robert A. Robinson, MD, PhD
Mucoepidermoid carcinoma is composed of cells with squamous 
and mucin producing cells along with clear, basal, and intermediate 
cells. Mucoepidermoid carcinoma is seen in the major salivary glands 
and in mucosal (minor) salivary glands. In the oral cavity, the palate 
is a common site. 
Historically the tumors have been graded into three categories, low, 
intermediate and high or a corresponding numerical system of Grades 
1, 2 or 3. In general, tumors that are Grade 1 exhibit minimal nuclear 
pleomorphism. (Figure 1) They also show a large cystic component. 
(Figure 2) Grade 3 tumors almost always exhibit significantly more 
nuclear atypia and show a marked amount of atypical squamous 
differentiation along with a desmoplastic response. (Figure 3) They 
can be difficult to separate from moderately differentiated squamous 
carcinoma. However, at times mucoepidermoid carcinomas that 
have an aggressive behavior can exhibit minimal nuclear atypia. 
This problem is addressed in the most recent grading systems for 
mucoepidermoid carcinoma, known as the Brandwein classification 
system by most. 
Focus	on	
Mucoepidermoid Carcinoma Grading
Mucoepidermoid Carcinoma Grading  
(Brandwein M, et al, Am J Surgical Pathology 2001:25(7):815-845.
Histopathologic Feature              Point Value
Intracystic component  < 25%          2
Tumor front invades in small nests and islands        2
Pronounced nuclear atypia          2
Lymphatic and or vascular invasion         3
Invasion of bone            3
Mitoses (>4/10 HPF)           3
Necrosis            3
Perineural spread           3
Grade I             0
Grade II          2–3
Grade III           >4
This system uses a point counting scale to arrive at a specific 
grade. Not only does nuclear atypia factor into the equation but 
also degree of cystic change, invasive characteristics, perineural 
invasion, necrosis, bone invasion and mitotic rate.
Recently we have seen a case example at UIHC that highlights the 
importance of using this grading system rather than an estimation 
of the degree of overall nuclear atypia of the tumor to adequately 
assess the biologic behavior of a mucoepidermoid carcinoma. 
Case Findings: 
Our patient presented with a mass in the submandibular gland. The 
tumor was found to be extensively invasive at the time of surgery 
with involvement of numerous nearby tissues. On histologic 
review the tumor was composed of mucus and squamous cells 
with minimal atypia but showing only minimal cystic components 
(2 points). (Figure 4) The histologic features of the tumor also 
included extensive perineural invasion (3 points) as well as 
a marked desmoplastic response and invasion into numerous 
margins with thin infiltrating cords of tumors (2 points). (Figures 
5 & 6) Using prior grading systems, this tumor would likely have 
been graded as Grade 1 based on the nuclear features. Using the 
Brandwein classification system, this tumor had a total of 7 points, 
which falls into the high grade or Grade 3 category. This grade 
is much more reflective of the biologic behavior of the neoplasm 
as seen at the time of operation and will influence the type of 
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Matthew Krasowski, MD, PhD 
Clinical Associate Professor, Vice-Chair for Clinical Affairs, Director of Clinical Laboratories
 Vitamin D was first recognized as a vitamin 
in the early twentieth century as a factor in 
cod liver oil that prevented the development 
of rickets, a debilitating syndrome of bone 
weakening in children that can lead to 
fractures and permanent skeletal deformity 
(e.g., ‘bowed’ legs).  In the last two decades, 
there has been increasing interest in the 
biology of vitamin D, as well as a growing 
recognition that vitamin D deficiency is 
common throughout the world including 
industrialized countries such as the United 
States.  One consequence of the growing 
clinical attention to vitamin D has been a 
substantial increase in laboratory testing 
for vitamin D.
The ‘classic’ actions of vitamin D are in 
the regulation of calcium and phosphate 
metabolism.  Vitamin D and parathyroid 
hormone (PTH) together serve as the most 
important physiologic regulators of calcium 
and phosphorus.  Prolonged vitamin D 
deficiency can lead to a sustained increase 
in PTH secretion, a condition known as 
secondary hyperparathyroidism that can 
cause dramatic loss of calcium from bones.
Medical research has demonstrated an 
increasing list of ‘non-classical’ vitamin 
D actions, including effects on immune 
system, cell growth, and brain health. 
Vitamin D deficiency has now been 
linked with increased risk of multiple 
sclerosis, certain cancers (especially 
breast, colorectal, and prostate cancers), 
and chronic respiratory infections (e.g., 
tuberculosis).  Consequently, vitamin D 
deficiency has health implications that 
extend well beyond skeletal abnormalities.
The term ‘vitamin D’ usually refers 
collectively to vitamin D2 (ergocalciferol) 
Vitamin	D
Deficiency & Testing
and vitamin D3 (cholecalciferol), together 
known as the calciferols.  Vitamin D2 
and D3 are hydroxylated in the liver 
to form 25-hydroxyvitamin D2 or D3. 
25-Hydroxyvitamin D is the main storage 
form of vitamin D and also the analyte 
typically measured in serum or plasma to 
assess vitamin D stores.  25-Hydroxyvitamin 
D is further hydroxylated in the kidney to 
form 1,25-dihydroxyvitamin D (calcitriol), 
which represents the biologically most 
active form of vitamin D in terms 
of effects at the vitamin D receptor. 
1,25-Dihydroxyvitamin D varies day-to-
day much more than 25-hydroxyvitamin D 
and is in fact not a good marker of overall 
vitamin D nutritional status.  In fact, it 
is possible to be profoundly deficient 
in overall stores of vitamin D yet have a 
1,25-dihydroxyvitamin D serum/plasma 
concentration within the reference range 
due to higher levels of PTH that cause 
greater conversion of 
25-hydroxyvitamin D to 
1,25-dihydroxyvitamin 
D.
There are a number of 
factors that contribute 
to vitamin D deficiency. 
The first is decreased 
endogenous production 
in the skin by exposure 
to ultraviolet B (UVB) 
rays (the same UV 
rays also associated 
with skin cancers).  In 
practical terms, optimal 
endogenous vitamin 
D3 production in response to sunlight in 
the northern latitudes requires sunlight 
exposure in the warmer months and 
during peak sunlight hours (approximately 
10:00 AM to 3:00 PM).  In the Northern 
Hemisphere above 35° latitude (roughly 
that of Atlanta, Georgia in the United 
States) essentially no vitamin D3 is 
produced endogenously from November to 
March even with direct sunlight exposure. 
Consequently, for many individuals in the 
United States (including Iowa) during the 
winter months, the only substantial source 
of vitamin D is from the diet.  Sunscreen 
use also dramatically decreases vitamin 
D production.  Sunscreens with sun 
protection factor (SPF) 15 or higher block 
99% or more of vitamin D production. 
Skin damage (e.g., burns, scars, keloids) 
can also reduce vitamin D production, 
depending on the extent of injury. 
The second main factor underlying vitamin 
D deficiency is low dietary intake.  There 
are a relatively small number of foods that 
naturally contain high amounts of vitamin 
D.  These include oily fish (e.g., mackerel), 
eggs, and Shiitake mushrooms.  The 
amount of vitamin D in supplements varies 
considerably.  Most multivitamins contains 
VITAMIN	D	IS	AN	ESSENTIAL	FAT-SOLUBLE	VITAMIN	THAT	
AFFECTS	NEARLY	EVERY	ORGAN	SYSTEM.
400 international units (IU) of vitamin D2 
or D3.  Vitamin D3 supplements generally 
contain 400, 800, 1000, or 2000 IU.  
There is a liquid supplement of vitamin 
D2 that contains 8,000 IU/mL and a 
prescription vitamin D2 capsule containing 
50,000 IU.  To enhance vitamin D intake 
on a population-wide basis, dairy products 
(e.g., milk, butter) may be supplemented 
with either vitamin D2 or D3.  It is 
important to keep in mind that dietary 
intake of vitamin D is often much less 
than could be achieved with 30 minutes 
of direct sunlight.  For example, sunlight 
equivalent to one minimal erythemal dose 
(just enough to achieve redness of skin 
in 24 hours) in summertime can result in 
20,000 IU of vitamin D3 production.  In 
contrast, 3.5 ounces of fresh wild salmon 
contains 600-1,000 IU of vitamin D3 while 
most fortified beverages and food (e.g., 
milk, orange juice) contain only 100 IU 
per serving.  Breast milk also contains low 
concentrations of vitamin D, especially 
in lactating women who themselves are 
vitamin D insufficient.
The third main factor that can contribute 
to vitamin D deficiency is malabsorption. 
Conditions that can reduce vitamin 
D absorption include use of bile acid 
sequestrants (e.g., cholestyramine, 
colesevelam), cystic fibrosis, celiac disease, 
Whipple’s disease, Crohn’s disease, and 
gastric bypass surgery.  These patient 
populations are also at risk for deficiency 
in other fat-soluble vitamins (A, E, and 
K).  In patients with these conditions, 
increased vitamin D supplementation may 
be indicated.  Alternatively, use of tanning 
beds at sub-tanning intensities can be 
highly effective in increasing vitamin D 
production in skin.
One of the major areas of discussion in 
the vitamin D literature is what should be 
the appropriate reference/target ranges 
for 25-hydroxyvitamin D.  There is rough 
consensus that 25-hydroxyvitamin D 
levels below 20 ng/mL are ‘deficient’. 
This is the threshold used by the World 
Health Organization.  What has been 
more difficult to define is an optimal 
level.  One physiologic approach to define 
25-hydroxyvitamin D ranges is to look at the 
relationship between 25-hydroxyvitamin D 
and PTH levels.  These show an inverse 
relationship with PTH concentrations rising 
as the 25-hydroxyvitamin D concentration 
decreases, allowing for the body to 
maintain adequate serum calcium levels. 
PTH begins to increase substantially when 
25-hydroxyvitamin D concentrations 
drop below 30-40 ng/mL, suggesting that 
25-hydroxyvitamin D levels below this 
range are not optimal, even though overt 
disease (e.g., rickets, osteomalacia, bone 
pain) may not be evident.
There are a number of methods for 
measuring 25-hydroxyvitamin D in serum/
plasma including enzyme immunoassay, 
radioimmunoassay, high-performance 
liquid chromatography (HPLC), liquid 
chromatography-mass spectrometry 
(LC/MS), and liquid chromatography/
tandem mass spectrometry (LC/MS/
MS).  One downside up to now has been 
that the available methods for measuring 
25-hydroxyvitamin D either require 
expensive instrumentation such as LC/
MS/MS that are generally feasibly only 
for reference laboratories or larger medical 
center laboratories, or are relatively slow 
and labor-intensive.
The exciting recent development is that 
automated assays for 25-hydroxyvitamin 
D have finally reached the U.S. market. 
Given that foods in the U.S. may contain 
either vitamin D2 or D3, the FDA has 
insisted that 25-hydroxyvitamin D assays 
equally detect both forms of vitamin D, 
which presented a technical challenge for 
diagnostic manufacturers that has only 
recent been overcome.  Recently, both 
Siemens Healthcare Diagnostics and Abbott 
Diagnostics have received clearances from 
the Food and Drug Administration (FDA) 
for 25-hydroxyvitamin D immunoassays 
that can run on high-throughput chemistry 
analyzers.  Other diagnostic manufacturers 
are also seeking FDA approval for their 
own 25-hydroxyvitamin D assays.  The 
availability of these immunoassays will 
allow smaller hospital laboratories to 
more easily perform 25-hydroxyvitamin D 
analysis.  The University of Iowa Hospitals 
and Clinics Core Chemistry laboratory 
brought  the 25-hydroxyvitamin D assay 
in-house in January 2012.  
Some key points regarding vitamin D 
testing:
(1) Routine screening should use an 
assay for 25-hydroxyvitamin D.  Testing 
for 1,25-dihydroxyvitamin D is rarely 
indicated.
(2) Although there is no consensus on 
reference ranges for 25-hydroxyvitamin 
D, most authorities recognize that serum 
levels below 20 ng/mL are clearly deficient, 
and that level between 20 and 30 ng/mL are 
probably not optimal.
References:  Holick MF.  Vitamin D deficiency. 
N Engl J Med 357(3): 266-281, 2007.
Krasowski MD.  Pathology consultation on 
vitamin D testing.  Am J Clin Pathol 136(4): 
507-514, 2011.
Questions may be directed to:
Matthew Krasowski, MD, PhD
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Aaron Bossler, MD, PhD 
Director, Molecular Pathology Laboratory
Although the 5-year survival rate has 
improved significantly during the past 20 
years, the rate of detection of metastatic 
disease continues to be a medical and 
socioeconomic problem. 
Progress has been made with the 
introduction of anti–epidermal growth 
factor receptor (EGFR) monoclonal 
antibodies including cetuximab or 
panitumumab. However, these targeted 
therapies are ineffective in patients 
with tumors that harbor mutations in 
the downstream signaling molecules of 
the EGFR pathway, ie, KRAS, NRAS, 
PIK3CA, and BRAF. These downstream 
genes are mutated in approximately 35% 
to 65% of cases with KRAS being most 
frequently mutated. Only patients with 
a KRAS wild type tumor are likely to 
respond to therapy, and the American 
Society of Clinical Oncology and the 
National Comprehensive Cancer Network 
recommend that all patients with metastatic 
colorectal cancer who are candidates for 
anti-EGFR antibody therapy should have 
their tumor tested for KRAS mutations.
Kirsten RAS (KRAS) is a member of 
the Ras oncogene family, which encodes 
small G proteins with intrinsic GTPase 
activity. GDP/GTP cycling is regulated by 
Accurate	Detection	of	
KRAS Mutations to Guide Proper 
Cancer Treatment Selection 
guanine nucleotide exchange factors (Ras-
GEFs) that promote formation of active 
Ras-GTP, whereas GTPase activating 
proteins (GAPs) stimulate GTP hydrolysis 
and formation of inactive Ras-GDP. In 
normal quiescent cells, Ras is GDP bound 
and inactive.  Extracellular stimuli (eg, 
epidermal growth factor) cause transient 
formation of the active, GTP-bound form 
of Ras. Activated Ras-GTP binds to a 
spectrum of downstream targets, which 
are involved in the regulation of cell 
proliferation, differentiation and survival 
through the MAK kinase as well as the PI3 
kinase signaling pathways.
The most common KRAS mutations are 
point mutations involving exon 2 and 3 
at codon 12, 13 and 61, more rarely, in 
codons 117 and 146. This spectrum of 
RAS mutations are all positioned in the 
same three-dimensional space of the folded 
protein. Mutations in RAS impairs its 
intrinsic GTP hydrolysis function resulting 
in constitutive activation of the protein, 
leading to stimulus independent, persistent 
activation of downstream effectors. 
Accurate detection of KRAS mutations 
is important for guiding proper treatment 
selection. Various methods have been 
described for the detection of KRAS 
mutations, and though Sanger DNA 
sequencing remains the gold standard for 
detecting any variation in the gene, it has a 
poor limit of detection of approximately 20%. 
The Molecular Pathology Laboratory in the 
Department of Pathology at the University 
of Iowa Hospitals and Clinics (UIHC) has 
developed a PCR-based single nucleotide 
primer extension assay that detects KRAS 
mutation in codons 12, 13 and 61. 
The sensitivity of the assay is 2-5% of 
mutant allele in the background of wild 
type allele from formalin-fixed paraffin-
embedded tissue specimens. Tissue sections 
are reviewed by a pathologist before testing 
to determine whether sufficient material is 
present, and specimens with minimal tumor 
cells may be rejected. Genomic DNA is 
isolated from the selected area with tumor, 
quantified and amplified by polymerase 
chain reaction (PCR) using primers to 
exons 2 and 3 of the KRAS gene. PCR 
products are subjected to single nucleotide 
primer extension followed by capillary gel 
electrophoresis and fluorescence detection. 
The absence or presence of a specific 








Questions may be directed to:
Molecular Pathology Laboratory Faculty:  
Aaron Bossler, MD, PhD, Director  
Phone: 319-384-9566 
e-mail:  aaron-bossler@uiowa.edu 
Jonathan Heusel, MD, PhD
Phone: 319-356-8616
e-mail:  jon-heusel@uiowa.edu 
Deqin Ma, MD, PhD 
Phone: 319-384-5700
e-mail:  deqin-ma@uiowa.edu 
Robert A. Robinson, MD, PhD
UIDL Medical Director  
Phone: 319-356-4163 

















This assay detects mutations in codons 12, 13, and 61 (total of 19 mutations).  The presence 
of mutation may indicate lack of responsiveness to anti-EGFR therapy for patients with 
colorectal, lung, breast or other cancers for which cetuximab (Erbitux) or panitumumab 
(Vectibix) are used.  Advanced PCR and Single Nucleotide Primer Extension technology. 
Go to the UIDL Test Directory:  KRAS
NEW:		Vitamin	D,	25-HYDROXY
This immunoassay is the appropriate screening test for routine assessment of vitamin D 
nutritional status.  This assay accurately quantifies the sum of vitamin D3, 25-Hydroxy 
and vitamin D2, 25-Hydroxy.  Optimum 25-hydroxy vitamin D concentration is 30 ng/mL 
or higher.  For workup for hypercalcemia, vitamin D status in renal failure patients, and 
certain malignancies, “Vitamin D (1,25-dihydroxy)” may be indicated.  
Go to the UIDL Test Directory:  Vitamin D
NEW:		LARGE	DNA	Sequencing
Mutations in the LARGE gene cause muscular dystrophies in the dystroglycanopathy
spectrum. Walker-Warburg syndrome (WWS; OMIM 236670), a severe congenital 
muscular dystrophy (CMD) with defective neuronal migration and associated structural 
brain and eye abnormalities, is the most severe manifestation (Godfrey et al. Brain 
130:2725-2735, 2007). At least one patient with congenital muscular dystrophy (MDC1D; 
OMIM 608840) and LARGE mutations has been described (Longman et al. Hum Mol 
Genet 12:2853-2861, 2003).
The dystroglycanopathies are inherited in an autosomal recessive manner. Like-
acetylglycosaminyltransferase (LARGE) activity is necessary for proper post translational 
processing of the protein, alpha-dystroglycan (ADG). In the absence of this enzyme, 
ADG remains hypoglycosylated and diverse pathologies follow (Barresi and Campbell, 
J Cell Science 119:199-207, 2006).  Molecular diagnosis (and classification) of the 
dystroglycanopthy subtypes is complex because extensive locus heterogeneity exists for 
each disorder (Godfrey et al. Brain 130:2725-2735, 2007), and because the phenotypes 
caused by the six demonstrated and putative glycosyltransferase genes continue to expand 
(e.g. van Reeuwijk et al. Hum Mut 27:453-459, 2006). 
Evaluation of a patient’s muscle biopsy by immunofluorescence can detect abnormal 
glycosylation of ADG and can, therefore, help direct a diagnostic evaluation. It should 
be noted that five other genes (POMT1, POMT2, POMGnT1, FKRP, FKTN) encode 
proteins required for processing of ADG.  This test is indicated for individuals with 
symptoms consistent with WWS or CMD or individuals with immunofluorescence results 
demonstrating hypoglycosylation of ADG in muscle.
Go to the UIDL Test Directory:  LARGE DNA Sequencing
UIDL Corner








SPONSORED BY:  University of Iowa Roy J. and Lucille A. Carver College of Medicine and the Department of Pathology
SCIENTIFIC SESSIONS
Saturday, April 28 – Sheraton Hotel
  
8:30-10:00 am Gastrointestinal Pathology Session I	
10:00-10:20	 Break
10:20-11:50    Gastrointestinal Pathology Session II  															
	 INVITED	SPEAKER:	Dr.	Henry	Appelman
 M.R. Abell Endowed Professor of Surgical Pathology
 University of Michigan
11:50-1:00 pm Lunch	-	provided	at	Sheraton	Hotel
	
1:00-2:00 Chronic Hepatitis—Practical Evaluation of the Liver Biopsy	
																						 Dr.	Leana	Guerin
 Clinical Assistant Professor of Pathology, University of Iowa
	 						
2:00-3:00     Contemporary Surgical Pathology Reporting of  
 Colon Carcinoma
																						 Dr.	Andrew	Bellizzi	
	 Clinical Assistant Professor of Pathology, University of Iowa
3:00-3:15 Break
	
3:15-4:15     Endoscopic Ultrasound for the Practicing Pathologist 
																						 Dr.	Chris	Jensen	
 Clinical Professor of Pathology, University of Iowa
	 						
4:15-5:15     Gastrointestinal Pathology Vignettes- Whimsical Case  
 Presentations, each with a Teaching Point		
																						 Dr.	Frank	Mitros



























Dr. Michael Cohen, Professor of 
Pathology and Urology, recently 
received recognition for his dedication 
and hard work for the University of 
Iowa.  Dr. Cohen was awarded one of 
three annual Awards for Excellence 
in 2011.  The award was presented to 
Dr. Cohen by the UI Staff Council.  
Congratulations to Dr. Cohen for 
his hard work and dedication to the 
University of Iowa.
Dr. Cohen, Professor of Pathology 
and Urology in UI Carver College of Medicine and Professor 
of Epidemiology in the UI College of Public Health, has seen 
his work to study prostate cancer recognized through a Career 
Development Award from the American Cancer Society (1992) 
as well as almost continuous funding from the NIH. 
He has been an extremely effective teacher to an array of 
learning audiences, from high school students (in the Iowa 
Junior Science Program) to practicing professionals (through 
Continuing Medical Education), and many of his UI students 
and trainees have gone on to succeed as basic scientists, 
academic clinicians, and private practice pathologists. 
He has been called a “devoted servant” to his colleagues and 
profession, with an impressive record of service that includes 
his role as Departmental Executive Officer of the Department 
of Pathology since 1999. He has served on numerous important 
collegiate and university-wide committees and has been a 
member and officer of the Faculty Senate.
Dr.	Rosenthal	Appointed	Bierring	Professor	of	
Clinical	Education
Please extend congratulations to Nancy 
Rosenthal, MD, Clinical Professor, 
Section Director, Hematopathology and 
Assistance Dean for Student Affairs, 
on her reappointment to the Bierring 






Effective February 1, 2012, Dr. Barry De 
Young has taken over as the Interim Head 
of the Department of Pathology.  Dr. 
Michael Cohen, who has stepped down 
as head, has been appointed Professor of 
Pathology at the University of Utah in 
Salt Lake City, and began his duties there 
February 1.
Dr. Barry De Young joined the UI Carver College of Medicine 
faculty in August of 2000.  He currently has appointments 
as a Clinical Professor in the Departments of Pathology and 
Orthopaedics and serves as Vice Chair for Faculty Affairs in 
Pathology and is currrently the Stamler Professor of Pathology.  
In addition, he is Director of Surgical Pathology and Director of 
the Surgical Pathology Fellowship Training Program.  He has 
received many honors and awards, and has served on collegiate 
and UI committees.  He is a member of several professional 
organizations and associations, including being a founding 
member of the International Society of Bone and Soft Tissue 
Pathology, serving as Secretary of the Arthur Purdy Stout Society 
of Surgical Pathologists, and a long-standing council member of 
the Association of Directors of Anatomic and Surgical Pathology.   
Dr. De Young’s research is primarily focused on projects that 
assist the surgical pathologist in arriving at an accurate diagnosis 
or in predicting patient prognosis for a given neoplasm.  His 
areas of active research include investigations with the proto-
oncogene Her2-neu in epithelial neoplasia.
Young	Investigator’s	Award	Presented	to	Matthew	
Krasowski,	MD	
The Therapeutic Drug Monitoring/
Toxicology (TDM/Tox) Division of 
the American Association for Clinical 
Chemistry sponsors an annual award 
designed to recognize young persons 
actively engaged in the laboratory 
practice of therapeutic drug monitoring 
or toxicology and contributing to the 
profession through research, publication, 
or teaching in these fields.   Matthew 
Krasowski, MD, PhD was selected by the 
TDM/Tox Awards Committee and received 
the Young Investigator’s Award at the 2011 AACC Annual 
Meeting held in Atlanta, Georgia, July 25-28, 2011.
Faculty AWARDS	AND	RECOGNITIONS
Matthew Krasowski
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Dr.	De	Young	appointed	to	Stamler	Professorship	
Dr. Barry De Young, Clinical Professor 
of Pathology, Director of Surgical 
Pathology, Vice Chair of Faculty Affairs, 
has been appointed to the Frederic W. 
Stamler Professorship in Anatomic 
Pathology. The five-year appointment 
was effective July 1, 2011. 
The professorship honors the long-
standing dedication and service of 
Frederic W. Stamler, M.D., a former 
UI professor of pathology who passed 
away in 2004. Stamler was a diagnostic 
pathologist, teacher and faculty member in the department for 
more than 40 years until his retirement in 1989.  He is nationally 
recognized for his work on improving diagnostic accuracy of 
tests used to assess cancers. The appointment recognizes  
De Young’s dedication and contributions to teaching and service 
in the department.
De Young earned a medical degree at the Georgetown University 
School of Medicine and completed residency training in 
anatomic pathology at Barnes Hospital. He also completed 
fellowships in surgical pathology at Barnes Hospital and at 
University of Virginia Health Science Center.
2011	Distinguished	Achievement	Award	
Recipient:	Stephen	Bonsib,	MD
The 2011 Department of 
Pathology Distinguished 
Achievement Award 
was created to honor 
individual faculty, 
alumni and friends of 
the department who 
have made significant 
and enduring clinical or 
scientific contributions 
in pathology.  The 
Distinguished 
Achievement Award 
recipient for this year was presented to Stephen M. Bonsib, 
MD, Professor and Chairman of Pathology at Louisiana State 
University Health Sciences Center, Shreveport, Louisiana, by  
Dr. Michael Cohen, MD, Head of the UI Department of Pathology.  
Dr. Bonsib graduated from Indiana University School of 
Medicine and received his pathology training at the University 
of Iowa. He  completed fellowships in Renal and Surgical 









The 2011 Clinical Achievement Award recognizes a clinical 
and an anatomic pathology faculty member for their significant 
achievement in the creation and delivery of clinical services 
John Kemp, MD, Professor of Immunopathology and Associate 
Chair for Quality, Safety, and Performance Improvement, had the 
distinct honor of presenting the awards to the deserving recipients 
(pictured below).  
We are pleased to announce that this year’s anatomic pathology 
award was presented to Patricia Kirby, MD, and the clinical 
pathology award was presented to Matthew Krasowski, MD, PhD.  
2011	Resident	Teaching	Award	Recipient:			
Dennis	Firchau,	MD
Congratulations to Dennis Firchau, MD, Clinical Assistant 
Professor, Anatomic Pathology.  This award is given annually to 
a faculty member in the Department 
of Pathology who displays exemplary 
teaching and mentoring skills while 
working with the residents. While 
relatively new to the University of 
Iowa faculty, Dr. Firchau has made 
an immediate positive impact on the 
education and work of the pathology 
residents. Please see the full feature story 
on Dr. Firchau on page 19.
He is academically active in renal pathology and urologic 
pathology with over 120 publications and book chapters. He 
has had many invited activities at the American Society of 
Nephrology and the United States and Canadian Academy of 
Pathology Annual Meetings. He was President of the Renal 
Pathology Society in 2007. Dr. Bonsib has a keen interest in 
renal neoplasms. 
His seminal work in defining the principal pathway for 
extrarenal extension of renal cell carcinoma, involvement of 
the renal sinus, led to incorporation of this feature in the 2002 
AJCC TNM Staging System. This work has influenced how 
pathologists evaluate renal cancer resections.
Dr.	Mitros,	GI	and	Liver	Pathology,	Honored	as	
UIP	Best	Consulting	Provider	
The first-ever University of Iowa 
Physicians (UIP) Clinical Awards were 
presented October 17, 2011, at the UIP 
annual meeting. UIP is composed of the 
700-plus staff physicians who provide 
care at UI Hospitals and Clinics.
Earlier this year, the group established 
the awards to honor clinical excellence 
among their members. Nominations are 
accepted annually from any UIP member 
or participant and evaluated by the UIP 
Clinical Awards Committee.
This Best Consulting Provider Award is given to an individual 
in recognition of his or her outstanding consulting or specialized 
services to the inpatient and ambulatory patients of UI Health 
Care.  Dr. Frank Mitros has worked at UI Hospitals and Clinics 
for over 30 years, and in that time has served as the “ultimate” 
consultant to his colleagues. Among his many attributes is his 
willingness to consult when he’s not “on call,” whether it’s after 
hours or on the weekends. Dr. Mitros’s knowledge, dedication to 
patients, willingness to go the extra mile, and ability to educate 
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Andrew Bellizzi, MD
Course #33 
Evolving Concepts in Colorectal Neoplasia;  A Survival 
Guide for 2012
Robert A. Robinson, MD, PhD
Course #25
Common Diagnostic Problems in Head and Neck 
Tumors:  A Combined Cytologic and Surgical Pathology 
Approach
Robert A. Robinson, MD, PhD
Steven D. Vincent, DDS, MS
Course #37 
Oral and Maxillofacial Pathology for the Practicing 
Pathologist: Pathology of Odontogenic and Other 
Common Lesions of the Jaws with Clinical and 
Radiographic Correlation
UI Faculty Presenting at 













B.S., B.A. University of Notre Dame, 2000
M.D. Northwestern University, Feinberg School of 
Medicine, 2004
Pathology Residency, University of Virginia Health 
System, 2004-2008
Chief Resident, University of Virginia Health System, 
2007-2008
Gastrointestinal/Liver Pathology Fellowship, The Ohio 
State University Medical 
Center, 2008-2009
Former Faculty member at Brigham & Women’s 
Hospital, Boston, MA
Dr. Bellizzi is a diagnostic surgical pathologist with 
subspecialty expertise in gastrointestinal, liver, and 
pancreatobiliary pathology. Special areas of interest 
include colorectal neoplasia and hereditary cancer 
syndromes. His research interests lie in pushing the 
bounds of the H&E-stained glass slide and readily 
available ancillary techniques, with the goal of 
increasing the diagnostic accuracy and prognostic 
and therapeutic relevance of our product (i.e., the 
pathology report). 
Dr. Bellizzi will be presenting the short course #33 - 
Evolving Concepts in colorectal Neplasia;  A Survival 
Guide for 2012 on Thursday, March 22, 2012, at 
the upcoming USCAP 101st Annual Meeting in 
Vancouver, British Columbia, Canada. 
Carol Holman, MD, PhD
Hematopathology




B.S. Valparaiso University, 1990
Medical Scholars Program, University of Illinois, 1999
Ph.D. University of Illinois, Urbana, 1997
M.D. University of Illinois, Urbana, 1999
AP/CP Residency, University of Minnesota, 2003
Hematopathology Fellowship, University of Minnesota, 2005
Dr. Holman joins us from the University of Minnesota where 
she was a faculty member. Dr. Holman’s clinical duties and 
interests include clinical diagnosis of patients with leukemia and 
lymphoma, as well as optimal laboratory testing for detection of 
minimal residual disease following therapy. 
She has research interests in the pathogenesis of Epstein-Barr 
virus infection and its role in a variety of diseases including 
post-transplant lymphoproliferative disorder, lymphomatoid 
granulomatosis, and infectious mononucleosis.
Amani Bashir, MB, BS
Surgical and Cytopathology
Clinical Assistant Professor 




M.B., B.S., University of Jordan Amman, Jordan, 1998
Intern, Jordan University Hospitals, Amman, Jordan, 
1998-99
Pathology Resident, University of Jordan, Amman, 
Jordan, 1999
Pathology Residency, The University of Iowa, 2000-04
Cytopathology Fellowship, The University of Iowa, 
2004-05
Surgical Pathology Fellowship, The University of Iowa, 
2005-06
Fellow Associate, The University of Iowa, 2006-07
Dr. Bashir’s primary interests are Surgical Pathology 
with special interest in breast, gynecologic and urologic 
pathology and Cytopathology special interests in 
performing and interpreting fine needle aspirations and 
an interest in salivary gland cytology.





e-mail:   deqin-ma@uiowa.edu
M.D. Shandong Medical University, Jinan, P.R. China, 1988
Ph.D. University of Kentucky Medical Center, Lexington, KY, 1998 
Anatomic Pathology Residency, National Cancer Institute/NIH, 
Bethesda, MD, 2006-2009
Molecular Genetic Pathology Fellowship, MD Anderson Cancer 
Center, Houston, TX, 2009-2010
Surgical Pathology Fellowship, University of Pennsylvania, 
Philadelphia, PA, 2010-2011                         
                                      
Dr. Ma’s clinical duties include both molecular genetic 
pathology and surgical pathology.  She has a special interest in 
molecular test development on solid tumors and hematopoietic 
malignancies. She is also interested in general surgical 
pathology.  Her research primarily is focused on studying the 
mechanism of tumor suppressor and metastatic suppressor.
The UI Department of Pathology is continually growing and expanding.  We have recently added a number 
of prominent faculty members and we are very happy to have them as a part of our team.  Please join us in 
welcoming Andrew Bellizzi, MD, Amani Bashir, MB, BS, Carol Holman, MD, PhD, and Dequin Ma, MD, PhD.  
New PATHOLOGY	FACULTY





Jonathan Braun, MD, PhD 
Professor and Chairman
Department of Pathology and Laboratory Medicine
Co-Director, Institute of Molecular Medicine





The 6th Annual Pathology Research Day held on October 11, 2011, was a chance for 
Pathology’s researchers to share their research topics, latest findings and knowledge 
about topics inherent to their daily work and career. The day included a full schedule 
of presenters covering a variety of research topics. Thirty two research posters were 
also displayed throughout the day.
DR. GARY BAUMBACH received a 
notice of R01 funding from the National 
Institutes of Health.  The title of the 
project is Cerebrovascular Structure 
in Hypertension: Mechanisms and 
Contributions to Stroke. This award is for 
the period of September 1, 2011 through 
July 31, 2016. The amount of this award is 
$1,651,563. 
DR. AARON BOSSLER has received a 
research continuation to extend the studies 
with Roche Molecular Systems, Inc. for a 
research project titled Early Evaluation of 
the New Cobas 4800 Instrument System. 
The amount of this contract continuation is 
$53,125. 
DR. FRED DEE received an Innovations 
in Teaching with Technology Award 
from the University of Iowa Academic 
Technologies Advisory Council. The 
title of the project is Development and 
Assessment of a Web-based Student 
Generated Cause and Effect Diagrams in 
Science and Education. The amount of this 
award is $30,000. 
DR. DANIEL DIEKEMA has a new 
research contract negotiated with 
PurThread Technologies, Inc. for a 
research project titled Efficacy of Pur 
Thread hospital privacy curtains in 
reducing privacy curtain contamination.  
The contract total is $22,063.  This 
contract is for the period of August 26, 
2011 through December 19, 2011.
Alicia Olivier, DVM, PhD, Assistant Professor 
Altered endocrine pancreas function prior to parenchymal destruction in newborn 
cystic fibrosis ferrets
Joe Mitros, MD, Surgical Pathology Fellow 
Lipogranulomas, pigment, and hepatitis C
Marina Ivanovic, MD, FIAC, Associate Professor
MTA-1 as a prognostic factor for aggressive prostate cancer
Ken Blackwell, BA, Research Associate 
New mechanistic Insights in TNFα-induced NF-κB activation
Ann Simons-Burnett, PhD, Assistant Professor 
Role of NOX4 in autophagy and IL6 expression in head and 
neck cancer cells 
Huy Nguyen, MS, Graduate Student 
Dystroglycan in cerebellar development and diseases
Adam Dupuy, PhD, Assistant Professor 
The adaptive immune system does not strongly suppress spontaneous tumors in a 




DR. DANIEL DIEKEMA has a 
new research contract negotiated 
with Innovative Biosensors, Inc. for a 
research project titled Evaluation of the 
BioFlash-Dx System for Rapid Detection 
of Methicllin Resistant Staphylococcus 
aureus (MRSA).  The contract total is 
$62,500.  This contract is for the period of 
August 25, 2011 through August 25, 2013.
DR. DANIEL DIEKEMA has a new 
research contract negotiated with 
Cerexa, Inc. for the continuation of a 
research project titled In Vitro Activity of 
Ceftaroline Versus Staphylococcus Aureus. 
The contract total is $609,500.  This 
contract is for the period of August 4, 2011 
through December 31, 2012. 
DR. FIORENZA IANZINI received a 
notice of new funding from the National 
Aeronautics and Space Administration 
(NASA). The title of the project is 
Mechanisms of Cell Survival Following 
Space Radiation-Induced Mitotic 
Catastrophe: Implications for Cancer 
Risk. This award is for the period of 
December 1, 2010 through November 
30, 2011. The amount of this award is 
$365,000.
DR. SIEGFRIED JANZ received 
notice of funding from the International 
Waldenstrom’s Macroglobulinemia 
Foundation (IWMF) for a research project 
titled Development of a Transgenic 
Mouse Model of Waldenstrom’s 
Macroglobulinemia. This award total is 
$540,000 and is for the period of August 
1, 2010 through July 31, 2012.
DR. STEVEN MOORE has a 
supplemental award from the Jain 
Foundation, Inc. for a research project 
titled Dysferlin Antibodies. The 
supplemental award total is $2,031. This 
award is for the period of June 15, 2011 
through June 14, 2012.
DR. THOMAS RAIFE received an 
Institute for Clinical and Translational 
Science (ICTS) Pilot Grant. The title of 
the project is Genetic Determinants of 
the Red Blood Cell Storage Lesion. The 
amount of this award is $50,000. This 
award is for the period of June 1, 2011 
through May 31, 2012. 
DR. THOMAS WALDSCHMIDT 
received a notice of NIH R01 subcontract 
funding from Dr. Michael Cho at Iowa 
State University. The title of the project is 
Enhancing B Cell Immunity Against HIV-1 
Using Novel Vaccine Delivery Platforms. 
This subcontract is for the period of 
August 1, 2010 through July 31, 2015. The 
total amount of this award is expected to 
be $525,000.
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Faculty 
RESEARCH	PUBLICATIONS
Hypertrophic Spinal Pachymeningitis 
With Thoracic Myelopathy: The Initial 
Presentation of ANCA-related Systemic 
Vasculitis.
Smucker JD, Ramme AJ, Leblond RF, 
Bruch LA, Bakhshandehpour G.
J Spinal Disord Tech. 2011 Mar 22
An enhanced antigen-retrieval protocol for 
immunohistochemical staining of formalin-
fixed, paraffin-embedded tissues.
Syrbu SI, Cohen MB.
Methods Mol Biol. 2011;717:101-10. 
A report on the piloting of a novel 
computer-based medical case simulation 
for teaching and formative assessment 
of diagnostic laboratory testing.
Kreiter CD, Haugen T, Leaven T, Goerdt 
C, Rosenthal N, McGaghie WC, Dee F.
Med Educ Online. 2011 Jan 14;16. doi: 
10.3402/meo.v16i0.5646.
The ARF tumor suppressor inhibits 
tumor cell colonization independent 
of p53 in a novel mouse model of 
pancreatic ductal adenocarcinoma 
metastasis.
Muniz V, Barnes JM, Paliwal S, Zhang 
X, Tang X, Chen S, Zamba KD, Cullen 
JJ, Meyerholz DK, Meyers S, Davis N, 
Grossman SR, Henry MD, Quelle DE.
Mol Cancer Res. 2011 Jun 2. 
Reappraisal of the provisional entity 
primary cutaneous CD4+ small/medium 
pleomorphic T-cell lymphoma: A series 
of 10 adult and pediatric patients and 
review of the literature.
Baum CL, Link BK, Neppalli VT, Swick 
BL, Liu V.
J Am Acad Dermatol. 2011 Jun 3. 
Observations on use of montelukast 
in pediatric eosinophilic esophagitis: 
insights for the future.
Stumphy J, Al-Zubeidi D, Guerin L, 
Mitros F, Rahhal R.
Dis Esophagus. 2011 May;24(4):229-34. 
doi: 10.1111/j.1442-2050.2010.01134.x. 
2010, Wiley Periodicals, Inc. and the 
International Society for Diseases of the 
Esophagus.
Pre-emptive eculizumab and 
plasmapheresis for renal transplant in 
atypical hemolytic uremic syndrome.
Nester C, Stewart Z, Myers D, Jetton J, 
Nair R, Reed A, Thomas C, Smith R, 
Brophy P.
Clin J Am Soc Nephrol. 2011 
Jun;6(6):1488-94. 
Efficacy and safety of EMR to 
completely remove Barrett’s esophagus: 
experience in 41 patients.
Gerke H, Siddiqui J, Nasr I, Van Handel 
DM, Jensen CS.
Gastrointest Endosc. 2011 Oct;74(4):761-71. 
Disseminated subarachnoid chordoma: 
long-term favorable follow-up of a 
pediatric patient.
Anderson S, Sato Y, Kirby P, Buatti JM, 
Menezes A.
Pediatr Radiol. 2011 Oct 9
Slow disease progression in a C57BL/6 
pten-deficient mouse model of prostate 
cancer.
Svensson RU, Haverkamp JM, Thedens 
DR, Cohen MB, Ratliff TL, Henry MD.
Am J Pathol. 2011 Jul;179(1):502-12. 
TOFA (5-tetradecyl-oxy-2-furoic acid) 
reduces fatty acid synthesis, inhibits 
expression of AR, neuropilin-1 and 
Mcl-1 and kills prostate cancer cells 
independent of p53 status.
Guseva NV, Rokhlin OW, Glover RA, 
Cohen MB.
Cancer Biol Ther. 2011 Jul 1;12(1):80-5. 
doi: 10.4161/cbt.12.1.15721.
Evidence of Spread of the 
Emerging Infectious Disease, Finch 
Trichomonosis, by Migrating birds.
Lawson B, Robinson RA, Neimanis 
A, Handeland K, Isomursu M, Agren 
EO, Hamnes IS, Tyler KM, Chantrey J, 
Hughes LA, Pennycott TW, Simpson VR, 
John SK, Peck KM, Toms MP, Bennett M, 
Kirkwood JK, Cunningham AA.
Ecohealth. 2011 Sep 21.
Consensus Statement on Effective 
Communication of Urgent Diagnoses 
and Significant, Unexpected Diagnoses in 
Surgical Pathology and Cytopathology 
From the College of American 
Pathologists and Association of Directors 
of Anatomic and Surgical Pathology.
Nakhleh RE, Myer JL, Allen TC, Deyoung 
BR, Fitzgibbons PL, Funkhouser WK, 
Mody DR, Lynn A, Fatheree LA, Smith AT, 
Lal A, Silverman JF.
Arch Pathol Lab Med. 2011 Oct 13. 
Leiomyosarcoma of the head and neck: 
a population-based analysis.
Eppsteiner RW, Deyoung BR, Milhem 
MM, Pagedar NA.
Arch Otolaryngol Head Neck Surg. 2011 
Sep;137(9):921-4.
Matching residents to pathology 
fellowships: the road less traveled?
Myers JL, Yousem SA, DeYoung BR, 
Cibull ML; Council of the Association 
of Directors of Anatomic and Surgical 
Pathology.
Am J Clin Pathol. 2011 Mar;135(3):335-7.
A case of solitary Blastomyces 
dermatitidis meningitis.
Dobre MC, Smoker WR, Kirby P.
Clin Neurol Neurosurg. 2011 
Oct;113(8):665-7.
Postmortem gastric perforation 
(gastromalacia) mimicking abusive injury 
in sudden unexplained infant death.
Laczniak AN, Sato Y, Nashelsky M.
Pediatr Radiol. 2011 May 24.
Recent Iowa Trends in Sudden 
Unexpected Infant Deaths: The 
Importance of Public Health 
Collaboration With Medical Examiners’ 
Offices.
Harris ML, Massaquoi D, Soyemi K, 
Brend SM, Klein D, Pentella M, Kraemer J, 
Nashelsky M, Schmunk G, Smith T, Pleva A.
Am J Forensic Med Pathol. 2011 Jul 20. 
A reduced segment II/III graft for 
neonatal liver failure with absence of 
detectable hepatocytes. A case report 
and literature review.
Alawi K, Mitros FA, Bishop WP, Rayhill 
S, Wu Y.
Pediatr Transplant. 2011 May;15(3):e60-3. 
doi: 10.1111/j.1399-3046.2009.01276.x.
Hepatitis C virus infection and hepatic 
stellate cell activation downregulate 
miR-29: miR-29 overexpression reduces 
hepatitis C viral abundance in culture.
Bandyopadhyay S, Friedman RC, Marquez 
RT, Keck K, Kong B, Icardi MS, Brown 
KE, Burge CB, Schmidt WN, Wang Y, 
McCaffrey AP.
J Infect Dis. 2011 Jun 15;203(12):1753-62.
Congenital pancytopenia and absence 
of B lymphocytes in a neonate with a 
mutation in the ikaros gene.
Goldman FD, Gurel Z, Al-Zubeidi D, 
Fried AJ, Icardi M, Song C, Dovat S.
Pediatr Blood Cancer. 2011 May 5. doi: 
10.1002/pbc.23160.
Pathology consultation on vitamin d 
testing.
Krasowski MD.
Am J Clin Pathol. 2011 Oct;136(4):507-14.
A comparative study of the sulfation 
of bile acids and a bile alcohol by the 
Zebra danio (Danio rerio) and human 
cytosolic sulfotransferases (SULTs).
Kurogi K, Krasowski MD, Injeti E, Liu 
MY, Williams FE, Sakakibara Y, Suiko M, 
Liu MC.
J Steroid Biochem Mol Biol. 2011 Aug 4.
In silico repositioning of approved 
drugs for rare and neglected diseases.
Ekins S, Williams AJ, Krasowski MD, 
Freundlich JS.
Drug Discov Today. 2011 Apr;16(7-
8):298-310.
Aberrant activation of ERK/FOXM1 
signaling cascade triggers the cell 
migration/invasion in ovarian cancer cells.
Lok GT, Chan DW, Liu VW, Hui WW, 
Leung TH, Yao KM, Ngan HY.
PLoS One. 2011;6(8):e23790. 
Benefit or burden? Sending patients with 
nonresectable lung cancer to the ICU.
Chooljian DM, Liu V.
Chest. 2011 Aug;140(2):558. 
Cutaneous Rosai-Dorfman disease 
following pneumococcal vaccination.
Bassis AV, Fairley JA, Ameln RT, Swick BL.
J Am Acad Dermatol. 2011 Oct;65(4):890-2. 
Treatment options for hyperhidrosis.
Walling HW, Swick BL.
Am J Clin Dermatol. 2011 Oct 
1;12(5):285-95. doi: 10.2165/11587870-
000000000-00000.
Simulation of cutaneous Bowen’s 
disease by freeze artifact in tissue 
briefly fixed in formalin.
Walling HW, Swick BL.
Int J Dermatol. 2011 Jun;50(6):757-8. doi: 
10.1111/j.1365-4632.2009.04503.x. 
Localized acral pityriasis lichenoides 
chronica: report of a case.
Halbesleben JJ, Swick BL.
J Dermatol. 2011 Aug;38(8):832-4. doi: 
10.1111/j.1346-8138.2010.01089.x. 
T regulatory cells participate in the 
control of germinal centre reactions.
Alexander CM, Tygrett LT, Boyden AW, 
Wolniak KL, Legge KL, Waldschmidt TJ.
Immunology. 2011 Aug;133(4):452-68. 
doi: 10.1111/j.1365-2567.2011.03456.x.
Multiple CD4+ T Cell Subsets Produce 
Immunomodulatory IL-10 During 
Respiratory Syncytial Virus Infection.
Weiss KA, Christiaansen AF, Fulton RB, 
Meyerholz DK, Varga SM.
J Immunol. 2011 Sep 15;187(6):3145-54.
Cell of origin strongly influences genetic 
selection in mouse models of T-ALL.
Berquam-Vrieze KE, Nannanpaneni K, 
Brett BT, Holmfeldt L, Ma J, Zagorodna 
O, Jenkins NA, Copeland NG, Meyerholz 
DK, Knudson CM, Mullighan CG, 
Scheetz TE, Dupuy AJ.
Blood. 2011 Aug 9.
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T-cell immunoglobulin and mucin 
domain 1 (TIM-1) is a receptor for 
Zaire Ebolavirus and Lake Victoria 
Marburgvirus.
Kondratowicz AS, Lennemann NJ, Sinn 
PL, Davey RA, Hunt CL, Moller-Tank 
S, Meyerholz DK, Rennert P, Mullins 
RF, Brindley M, Sandersfeld LM, Quinn 
K, Weller M, McCray PB Jr, Chiorini J, 
Maury W.
Proc Natl Acad Sci U S A. 2011 May 
17;108(20):8426-31. 
Case report: successful treatment 
of recurrent focal segmental 
glomerulosclerosis with a novel 
rituximab regimen.
Stewart ZA, Shetty R, Nair R, Reed 
AI, Brophy PD. Department of Surgery, 
University of Iowa Hospitals and Clinics, 
Iowa City, Iowa.
Transplant Proc. 2011 Dec;43(10):3994-6.
Hard, pink nodules on the upper 
extremities. Peripheral siliconomas.
Fernandez KH, Wollner J, Stone MS. 
University of Iowa, Iowa City, Iowa, USA.
Arch Dermatol. 2011 Oct;147(10):1215-20.
Therapeutic blockade of PD-L1 and 
LAG-3 rapidly clears established blood-
stage Plasmodium infection.
Butler NS, Moebius J, Pewe LL, Traore B, 
Doumbo OK, Tygrett LT, Waldschmidt 
TJ, Crompton PD, Harty JT. Department 
of Microbiology, University of Iowa, Iowa 
City, Iowa, USA.
Nat Immunol. 2011 Dec 11. doi: 10.1038/
ni.2180. 
Systemic inflammation with multiorgan 
dysfunction is the cause of death 
in murine ligation-induced acute 
pancreatitis.
Yuan Z, Meyerholz DK, Twait EC, 
Kempuraj D, Williard DE, Samuel I.
J Gastrointest Surg. 2011 
Oct;15(10):1670-8. 
An inducible model of abacterial 
prostatitis induces antigen specific 
inflammatory and proliferative changes 
in the murine prostate.
Haverkamp JM, Charbonneau B, Crist 
SA, Meyerholz DK, Cohen MB, Snyder 
PW, Svensson RU, Henry MD, Wang HH, 
Ratliff TL.
Prostate. 2011 Aug 1;71(11):1139-50. doi: 
10.1002/pros.21327.
Dennis Firchau, MD 
Clinical Assistant Professor, Anatomic Pathology
B.S. Michigan State University, 2000
M.D. Wayne State University School of Medicine, 2004
Pathology Residency, Medical College of Wisconsin, 2004-08
Cardiovascular Pathology Fellowship, Mayo Clinic, 2008-09
Forensic Pathology Fellowship, Hennepin County Medical Examiner’s Office, 2009-10
Dennis Firchau, Assistant Professor 
Interviewed by Janet Delwiche, Residency 
Program Coordinator
“An excellent teacher…and tremendous 
addition to our program.”  “Clearly 
has in-depth knowledge of forensics…
and cardiac path – a great asset.”  
“Demonstrates an enthusiasm and 
passion for his discipline that engages 
the residents.”  “Overall, a pleasure to 
work with.”  Such are the terms that 
pathology residents at the University of 
Iowa Hospitals and Clinics use to describe 
Dennis Firchau, M.D., Clinical Assistant 
Professor of Anatomic Pathology.  Dr. 
Firchau, recipient of the 2011 Resident 
Teaching Award, joined the faculty in the 
fall of 2010 and has brought considerable 
skill and expertise in forensic and 
cardiovascular pathology to his teaching 
and work as a Deputy Medical Examiner 
of Johnson County. 
Recently, Dr. Firchau sat down with me 
to discuss what led him to pursue forensic 
pathology, share his observations of 
current trends in the field, and tell me what 
he likes about his job at UI Pathology.
How did you come to be interested in 
pathology, and ultimately, to choose 
forensics as a subspecialty?
Given my undergraduate microbiology 
background, I’ve always had a fondness for 
the microscope. Then during medical school, 
I really started to get interested in how 
pathology allows us to see with our own 
eyes the disease process and its effect on 
organs and the body.  Through my pathology 
rotations during medical school, I learned 
and started to appreciate how much the 
practice of pathology affects patient care.  As 
far as my interest in forensics, I remember 
a case I observed as a medical student that 
helped me see the importance that medico-
legal death investigation can have to issues 
with potential effects on the living.  There 
was a particular case that uncovered a lot of 
important findings that were unexpected, and 
facilitated a law enforcement investigation 
that had a significant impact on living 
people.  Even though the decedent was no 
longer alive, the forensic work enabled some 
degree of justice to be achieved.
What are some of the hot topics in your 
field right now?
I think anyone can spot the hot topics in 
forensic pathology by watching court tv 
shows and following news headlines because 
the issues are really out there for the public 
to see.  Forensic pathology is following the 
general trend in medicine by moving toward 
and emphasizing evidence-based practice—
by striving to generate scientifically reliable, 
reproducible and defensible products.  So 
again, anyone paying close attention can get 
a good sense of how certain evidence holds 
up in a court of law or to scientific scrutiny 
from case to case.
What do you like best about your job at 
UI Pathology?
Lots of things.  I enjoy the unique 
opportunity I have here to practice 
forensic and autopsy pathology as well 
as to sign out cardiac biopsies and other 
cardiovascular cases.  I’m especially 
pleased with the medical education 
opportunities that allow me to work with 
both medical students and residents.  This 
is a very collegial department, and I find 
that my interactions with other faculty 
pathologists and the residents make my 
job quite satisfying.
What’s the most unexpected thing that’s 
happened to you at work?
Oh, that would have to be winning the 
resident teaching award.  During my 
interview here, one of the things that 
drew me to Iowa was the department’s 
culture of faculty dedication to educating 
residents as well as medical students.  
Receiving the resident teaching award at 
the end of my first year in a department 
where I have colleagues who are among 
the best pathologists and most amazing 
teachers anywhere was quite humbling!
What is one thing you think your 
colleagues would be surprised to know 
about you?
I’m grossed out by mouths. Yep, 
examining mouths is my least favorite part 
of doing autopsies!
Outside of work, Dr. Firchau enjoys golfing, 
watching sports of all kinds, and listening 
to music (his tastes are wide-ranging and 
eclectic).  Dr. Firchau can be reached at his 







Two Exceptional Residents Receive 2011 George D. Penick 
Award for Excellence in Education
This year’s recipients of the George D. Penick 
Award for Excellence in Education are Ben 
Darbro, MD, PhD and Mike Gailey, DO. This 
award is presented annually to a Pathology 
Resident or Residents who display excellence in 
and commitment to the education and teaching of 
medical students, peers and clinical colleagues.
Ben Darbro Mike Gailey




We really appreciate our new iPads and I have seen 
many residents using them in very productive manners.  Just 
the other day I was able to research the incidence of carcinoids 
of the foregut during a discussion at the Friday morning GI 
conference.  One of the chief residents found the very article on 
lung cancer being presented by a faculty member and emailed 
it to us during the conference allowing us to see closeups of the 
pictures she was presenting on the screen.  
While Dr. Chris Jensen was presenting on pap smear cytology 
I saw more than one resident pull up the ASCCP management 
guidelines.  I believe we are using the iPads in many ways that 
benefit our education and we all appreciate the gift and, dare I 




BS -  Millersville University of 
Pennsylvania, 2006
MD -  University of Iowa, 2011 
OMAR JABER, MD
MD - University of Jordan, 2009
CAROLYN (“Carly”) RYSGAARD, MD 
BA - University of Minnesota, 2004
MD - University of Minnesota , 2011 
STEPHANIE FISCHER, MD
BS - University of Iowa, 2004
MD - University of Iowa, 2011
MARISA JACOB, MD 
MD - Spartan Health Sciences University, 
Saint Lucia, 2011
ANNA DOLEZAL, MD
BA, BS - Drake University, 2005
MD - University of Iowa, 2011
Resident Program UPDATE Resident Program UPDATE
Dr. Leslie Bruch, Pathology Residency 
Program Director, recently approached 
department leaders about supplementing 
our pathology resident training by 
providing iPad technology to each 
resident.  The department immediately 
responded and agreed to the proposal.  
The following objectives were identified 
for the project:
•  Discover innovative training and  
 educational uses
•  Determine clinical uses within our  
 systems
•  Investigate capabilities to increase  
 resident productivity
•  Recognize opportunities for increased  
 faculty productivity as well  
•  Determine potential for enhancement  
 of resident recruitment 
We are happy to report that the iPads 
have had an immediate and very positive 
impact on daily productivity and 
learning.  A pathology resident recently 
wrote this note to department leaders to 




As of January 1, 2012, leadership for the residency program is passing from Dr. Leslie Bruch to Dr. Chris Jensen.  
Dr. Bruch has been Program Director for the past four years and prior to that served as an Assistant Program 
Director after she joined the department in 2006.  Under her stewardship the residency program has remained 
strong and she has been integral in bringing outstanding trainees to the department as well as working to implement 
changes required by the Accreditation Council for Graduate Medical Education (ACGME).  
She has been actively involved in institutional GME activities, serving on many committees.  In addition, she was 
elected to serve on the National Council of Pathology Residency Program Directors (PRODS) which serves as the 
leadership body that defines and refines graduate medical education in pathology.  Dr. Bruch will continue to be 
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2011 - 2012 PATHOLOGY	HOUSE	STAFF	ROSTER
Each year, the Department of Pathology’s ability to offer outstanding care is enhanced by 
generous support from faculty, staff, and alumni who believe in the department and want 
to give back in an important way.  Patients and their families also give generously to show 
their appreciation for care that they or their loved ones have received.  These charitable 
gifts help maintain our tradition of world-class patient care and clinical advances by 
funding research, education, and special programs and projects. 
 
I hope you will consider—in addition to making an annual gift to the department—creating 
a gift that will benefit the department for generations to come. I can work with you and 
your professional advisors to determine the type of planned gift that best suits your 
situation. Including a bequest in your will or trust is one way to remember the department. 
Naming the department as a beneficiary of part of an IRA or other qualified retirement plan 
is another.  
If you are considering a planned gift for the UI Department of Pathology, here are a few 
things to keep in mind:
• The correct legal language for a gift to the department is as follows:  To   
 The State University of Iowa Foundation, to provide support for the Department of  
 Pathology in the University of Iowa Roy J. and Lucille A. Carver College of Medicine.
• Bequests are fully revocable: We understand that your first priority in planning   
 your estate will always be providing for your needs during your lifetime and then for  
 your loved ones and we recognize your right to revise your plans at any time   
 without any obligation to the college. As bequests occur only after your lifetime,   
 you do not have to part with any of the financial resources that you may later   
 require for your own needs.
• Gifts payable by beneficiary designation are also fully revocable: One type of gift  
 that is easily overlooked, but is especially appropriate for charitable uses, involves 
 using assets from IRA’s and qualified retirement plans. More than half of retirement  
 plan assets could eventually end up being forfeited to taxes if left to one or more   
 individual heirs—whereas those same assets, if left to a qualified charity, can pass  
 to the charity completely tax-free.  Naming a charity as a beneficiary of part   
 or all of an IRA or qualified retirement plan is as simple as contacting your plan   
 administrator to request a new beneficiary designation form.  Once received, write  
 the name of the charity along with the percentage of the plan you wish to direct to it.
• As a member of OREF you can create an endowed fund designating the UI   
 Department of Pathology as the recipient – and you may be able to create your own  
 named fund!  Please contact me directly for additional information.
• To learn more online:  Visit www.uifoundation.org/giftplanning for more   
 information about charitable bequests and gifts of retirement plan assets.
Making a planned gift to the department can help you in your own financial planning, and your 
gift ensures a better future for all those who receive care through the Department of Pathology.
For additional information about how planned gifts can advance the work of the 
department, contact Shelly J. Mott the UI Foundation’s Associate Director of Development, 
Roy J. and Lucille A. Carver College of Medicine/University of Iowa Hospitals and 
Clinics, at shelly-mott@uiowa.edu, or by phone at 319-335-3305 or 800-648-6973.
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New Technology helps 
residents with training.
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